PacBio - PACB Stock Price

US export sanctions targeting Asia and stringent biosafety regulations are restricting Pacific Biosciences (PACB) access to global sales markets. Pacific Biosciences (PACB) is implementing automated DNA analysis stations to minimize human error in laboratories. Growth is driven by scientific alliances and R&D, as asset valuations preclude mergers. The indicator stands at 1.95. This chart illustrates the asset's market value dynamics.

PACB - PacBio Corp Stock Quotes over the range 07/04/2022 - 11/14/2026

PacBio Corp (PACB) - metric breakdowns and financial figures

- stock value and consensus price forecast:

Price Chart Pacific Biosciences|PACB - Forecast Levels Chart

- issuer market value details:

Market Capitalization Pacific Biosciences of California|PACB - Enterprise Value

- book capitalization information:

Book Value per Share PacBio|PACB - Company Net Assets|Market Capitalization to Book Value Ratio pacb.com|PACB - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and market ratios statistics:

PACB - Net Profit|Projected Future Earnings Pacific Biosciences|PACB - Price to Earnings Ratio|Forward P/E Multiple PacBio Corp|PACB - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Pacific Biosciences of California|PACB - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) PacBio|PACB - Net earnings per share for the last four quarters|Quarterly EPS earnings growth pacb.com|PACB - Net earnings per share growth this year|Expected earnings per share growth for next year Pacific Biosciences

- total revenue and sales volume data:

PACB - Company Sales Revenue|Projected Sales Volume PacBio|PACB - Price-to-Revenue Ratio|Forward P/S Multiple Pacific Biosciences of California, Inc.

Summary company analytics:pacb.com

Price determines the market value of business ownership through the continuous trading mechanism, reflecting the aggregate expectations of participants regarding future cash flows. By analyzing linear price action, an investor assesses management stability, where smooth price movement confirms confidence in the leadership of Pacific Biosciences (PACB) in high-precision DNA sequencing and the potential of their unique SMRT technology for personalized medicine.

Analysis of competing companies